TKD Client Acquires Pharmaceutical Company
TKD client Positron Corporation (OTC: POSC), a Texas-based developer of nuclear imaging equipment, recently acquired Dose Shield Corporation for stock and cash valued in excess of $9 million. Dose Shield is a manufacturer of patented radiopharmaceutical devices designed for use in nuclear medicine applications.
Positron designs, manufactures, markets and supports advanced cardiac molecular imaging devices which enable physicians to diagnose and treat patients in the areas of cardiology, neurology and oncology. The acquisition of Dose Shield complements Positron’s line of molecular imaging systems, dose drawing systems and disease management software.
Peter Campitiello, a partner in TKD’s Corporate and Securities Practice Group, and associate Jeanette Baiardi represented Positron Corporation in the acquisition.
Prior results do not guarantee a similar outcome
Back to main News and Events page
|
